证券代码：300404 证券简称：博济医药 公告编号：2024-097 博济医药科技股份有限公司 特别提示： 1、本次注销 2020 年股票期权激励计划中已授予但尚未行权的部分股票期 权数量 27,440 份，涉及人数为 1 人；注销 2022 年股票期权激励计划中已授予但 尚未行权的部分股票期权数量为 39,200 份，涉及人数为 1 人。 特此公告。 博济医药科技股份有限公司董事会 关于部分股票期权注销完成的公告 2024 年 9 月 10 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1 2、公司已在中国证券登记结算有限责任公司深圳分公司完成了本次股票期 权的注销手续。 博济医药科技股份有限公司（以下简称"公司"）于 2024 年 8 月 23 日召开 第五届董事会第十次会议和第五届监事会第十次会议，审议通过了《关于注销部 分股票期权的议案》。根据公司《2020 年股票期权激励计划（草案）》等有关 规定，公司 1 名激励对象因个人原因离职导致其不再具备激励资格，公司注销其 已授予但尚未行权的股票期权 27,440 份。根据公司《2022 年股票期权 ...

博济医药科技股份有限公司（以下简称"公司"或"博济医药"）2021 年向 特定对象发行股票的募集资金按照相关法律、法规和规范性文件的规定在银行开 立了募集资金专项账户。近日，公司办理完成了部分募集资金专项账户的注销手 续，现将具体情况公告如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意广州博济医药生物技术股份有限公司 向特定对象发行股票注册的批复》（证监许可〔2020〕3230 号）同意注册，博济 医药向特定对象发行 A 股股票 33,450,584 股，发行价格 10.26 元/股，募集资金 总额 34,320.30 万元，扣除各项发行费用（不含增值税）678.63 万元，公司实际 募集资金净额为 33,641.67 万元。上述募集资金已于 2021 年 6 月 18 日全部到账， 经中兴华会计师事务所（特殊普通合伙）审验，并出具了《验资报告》（中兴华 验字（2021）第 410005 号）。 证券代码：300404 证券简称：博济医药 公告编号：2024-096 博济医药科技股份有限公司 关于部分募集资金专户完成销户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 ...

Group 1: Company Overview - Boji Pharmaceutical Technology Co., Ltd. is actively engaging with various securities firms for investor relations activities [2] - The company is led by Chairman and General Manager Wang Tingchun and Deputy General Manager and Board Secretary Wei Fangqun [2] Group 2: Market Demand and Performance - The clinical CRO market demand is stable, with large pharmaceutical companies showing increased enthusiasm for R&D [2] - In the first half of 2024, the company signed new clinical research service contracts worth 719 million yuan, a year-on-year increase of 60.99% [2] Group 3: Order Structure - In the first half of 2024, new orders were primarily from clinical research services, accounting for approximately 87%; preclinical research services accounted for about 10%, and other consulting services made up around 3% [3] - Chemical and biological drugs represented over 60% of the product categories, with the remainder being traditional Chinese medicine and medical devices [3] Group 4: Client Structure - The company has a diverse client base, primarily consisting of large pharmaceutical enterprises, with most revenue coming from domestic clients [3] - Future plans include assisting domestic companies in conducting clinical trials in the U.S. and serving local U.S. enterprises [3] Group 5: Profitability and Margins - The gross margin decreased in the first half of 2024 due to intensified market competition and rising clinical trial requirements, but the gross margin for core clinical research services remains stable, accounting for about 80% of total revenue [3] - The company anticipates that gross margins will stabilize as business volume increases and cost control measures are enhanced [3] Group 6: Strategic Partnerships - A strategic cooperation agreement was signed with Boao Jingfang to collaborate on innovative Chinese medicine projects, focusing on AI-driven drug development [4] - The partnership aims to establish a joint venture for rapid screening of traditional Chinese medicine formulations [4] Group 7: Revenue and Growth Projections - As of the end of June 2024, the company had signed contracts worth approximately 2.516 billion yuan, with an expected revenue recognition of about 412 million yuan in the second half of 2024 [4] - The company aims for a contract value increase of over 47.52% compared to 2023 [5] Group 8: Future Development Plans - The company plans to maintain its focus on clinical research services while expanding preclinical pharmaceutical research and drug evaluation services [5] - There is an emphasis on enhancing self-innovation capabilities and developing proprietary products [5] - The company is also exploring mergers and acquisitions to strengthen its market position [5]

博济医药科技股份有限公司 2024 年半年度募集资金存放与使用情况的专项报告 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》和《深圳证券交易所创业板上市公 司自律监管指南第 2 号——公告格式》等有关规定，博济医药科技股份有限公司 （原名"广州博济医药生物技术股份有限公司"，以下简称"公司"或"博济医 药"）董事会编制了截至 2024 年 6 月 30 日募集资金存放与实际使用情况的专项 报告。 一、 募集资金基本情况 经中国证券监督管理委员会《关于同意广州博济医药生物技术股份有限公司 向特定对象发行股票注册的批复》（证监许可〔2020〕3230 号）同意注册，公 司向特定对象发行 A 股股票 33,450,584 股，发行价格 10.26 元/股，募集资金总 额 34,320.30 万元，扣除各项发行费用（不含增值税）678.63 万元，公司实际募 集资金净额为 33,641.67 万元。上述募集资金已于 2021 年 6 月 18 日全部到账， 经中兴华会计师事务所 ...

广发证券股份有限公司 关于博济医药科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 广发证券股份有限公司（以下简称"广发证券"、"保荐机构"）作为博济 医药科技股份有限公司（以下简称"博济医药"、"上市公司"或"公司"）向 特定对象发行股票的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关规定，就公司使用部分暂时闲置 募集资金进行现金管理的事项进行了核查。具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意广州博济医药生物技术股份有限公司 向特定对象发行股票注册的批复》（证监许可〔2020〕3230 号）同意注册，公司 向特定对象发行 A 股股票 33,450,584 股，发行价格 10.26 元/股，募集资金总额 34,320.30 万元，扣除各项发行费用（不含增值税）678.63 万元，公司实际募集 资金净额为 33,641.67 万元。上述募集资金已于 2021 年 6 月 18 日全部到账，经 中兴华会计师事务所（特殊普通合伙）审验，并出具了《验 ...

广发证券股份有限公司 关于博济医药科技股份有限公司 使用暂时闲置自有资金进行现金管理的核查意见 广发证券股份有限公司（以下简称"广发证券"、"保荐机构"）作为博济 医药科技股份有限公司（以下简称"博济医药"、"上市公司"或"公司"）向 特定对象发行股票的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关规定，就公司使用部分暂时闲置 自有资金进行现金管理的事项进行了核查。具体情况如下： 一、本次使用闲置自有资金进行现金管理的基本情况 1、投资目的 为提高公司资金使用效率，在确保公司日常经营资金需求和资金安全的情况 下，合理利用暂时闲置自有资金进行现金管理，以更好地实现公司现金的保值增 值，保障公司股东的利益。 2、投资额度及期限 公司及子公司拟使用额度不超过人民币 2 亿元的闲置自有资金进行现金管 理，在上述额度内，资金可以滚动循环使用，且经公司第五届董事会第十次会议 审议通过之日起 12 个月内有效。 3、投资品种 公司将按照相关规定严格控制风险，对理财产品进行严格评估，选择安全性 高、 ...

Business Strategy and Development - The company plans to leverage its unique "one-stop" service advantage to adjust its business structure and development direction in response to potential stricter NMPA new drug approval requirements[1]. - The company is expanding its business into preclinical research services and CDMO, but faces risks due to competition and lack of experience in these areas[3]. - The company has expanded its business from primarily clinical research services to a full industry chain of CRO services, increasing management complexity and risks associated with larger operational scale[68]. - The company plans to enhance its core competitiveness through strategic planning and project implementation, addressing the intensified market competition in the domestic pharmaceutical R&D outsourcing industry[68]. - The company has established a risk management framework to address potential operational risks arising from the expansion of its business scope and scale[68]. Financial Performance - The company's operating revenue for the first half of 2024 reached ¥341,390,828.56, representing a 46.92% increase compared to ¥232,360,196.30 in the same period last year[15]. - Net profit attributable to shareholders was ¥30,135,149.57, up 71.04% from ¥17,619,050.53 in the previous year[15]. - The net profit after deducting non-recurring gains and losses surged by 164.08%, amounting to ¥25,660,434.37 compared to ¥9,716,967.33 last year[15]. - The net cash flow from operating activities improved significantly to ¥4,790,796.04, a turnaround from a negative cash flow of ¥7,413,889.61 in the previous year[15]. - Basic earnings per share increased by 65.06% to ¥0.0789, while diluted earnings per share rose by 65.20% to ¥0.0788[15]. Revenue and Growth - The company achieved total operating revenue of ¥341,390,828.56, representing a year-on-year growth of 46.92%[28]. - The company secured new business contracts amounting to approximately ¥824 million, a year-on-year increase of about 47.52%[28]. - Revenue from clinical research services was ¥271,384,282.64, showing a year-on-year growth of 56.10%[28]. - The revenue from preclinical research services reached ¥41,795,073.84, representing a year-on-year increase of 46.18%[30]. - The company has assisted clients in obtaining over 70 new drug certificates and nearly 120 production approvals through its clinical research services[34]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,488,044,685.55, reflecting a 4.14% increase from ¥1,428,927,075.12 at the end of the previous year[15]. - The company's total liabilities reached CNY 492,572,061.26, compared to CNY 448,819,898.21, an increase of about 9.7%[134]. - The total owner's equity increased to CNY 995,472,624.29 from CNY 980,107,176.91, representing a growth of approximately 1.4%[134]. Investment and R&D - The company has invested significantly in R&D, with R&D expenses amounting to ¥26,820,863.07, a 14.34% increase from the previous year[41]. - The company has established a comprehensive preclinical evaluation service platform, which has passed GLP certification for various drug evaluations, enhancing its service capabilities[38]. - The company has undertaken innovative projects in diabetes and liver disease treatment, enhancing its portfolio in cutting-edge medical technologies[28]. Risk Management - The company emphasizes the importance of establishing good communication with clients to mitigate risks associated with contract execution and potential cost overruns[2]. - The company has faced risks related to contract execution, including potential delays and increased costs due to unforeseen circumstances during long-term drug development projects[67]. - The company has established specific responsibility models in contracts to manage risks associated with project delays and has implemented strict process management to minimize such occurrences[68]. Shareholder and Governance - The company will not distribute cash dividends, issue bonus shares, or increase capital from reserves[4]. - The company has maintained stable governance with no changes in its board of directors or senior management during the reporting period[72]. - The company emphasizes shareholder rights by adhering to legal requirements and ensuring timely and accurate information disclosure[87]. Environmental Compliance - The company has committed to environmental protection and compliance with national policies, reflecting a commitment to sustainable development[86]. - The company has established a solid waste management system and has reported hazardous waste types and disposal methods to local environmental authorities[85]. - The company has a valid wastewater discharge permit, effective until October 31, 2027[82]. Future Outlook - The company expects to engage in related party transactions totaling no more than 40.24 million yuan in 2024, which is within the approved limit[97]. - Future outlook includes plans for market expansion and potential acquisitions to enhance growth and market share[151].

北京市康达（广州）律师事务所 法律意见书 北京市康达（广州）律师事务所 关于博济医药科技股份有限公司 回购注销及作废部分限制性股票的 法 律 意 见 书 北京市康达（广州）律师事务所 BEIJING KANGDA LAW FIRM Guangzhou Branch 地址：广州市珠江新城珠江东路 32 号利通广场 29 层 邮政编码：510630 电话：020-37392666 传真：020-37392826 1 北京市康达（广州）律师事务所 法律意见书 北京市康达（广州）律师事务所 关于博济医药科技股份有限公司 回购注销及作废部分限制性股票的 法 律 意 见 书 致：博济医药科技股份有限公司 北京市康达（广州）律师事务所（下称"本所"）接受博济医药科技股份有 限公司（下称"博济医药"或"公司"）委托，根据《公司法》《证券法》等法律、 法规和规范性文件的有关规定，按照律师行业公认的业务标准、道德规范和勤勉 尽责精神就博济医药 2023 年限制性股票激励计划所涉及的相关事项出具法律意 见。为出具本法律意见书，本所及本所律师声明如下： 一、本所及本所律师依据《证券法》《公司法》《上市公司股权激励管理办法》 《深圳证 ...

证券代码：300404 证券简称：博济医药 公告编号：2024-091 博济医药科技股份有限公司 关于回购注销及作废部分限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博济医药科技股份有限公司（以下简称"公司"）于 2024 年 8 月 23 日召开 第五届董事会第十次会议和第五届监事会第十次会议，审议通过了《关于回购注 销及作废部分限制性股票的议案》，鉴于公司部分激励对象离职导致其不再具备 激励资格，同意公司回购注销其已授予但尚未解除限售的第一类限制性股票 10 万股；同意公司作废其已授予但尚未归属的第二类限制性股票 3 万股。根据相关 规定，本事项尚需提交公司股东大会审议。现将有关情况公告如下： 一、公司激励计划概述及已履行的相关程序 1、 2023 年 3 月 17 日，公司第四届董事会第二十五次会议审议通过了《关 于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事 会办理 2023 年限制性股票激励计划相关事宜的议案》等议案。同 ...

（二）本次计提资产减值损失的资产范围和总金额 证券代码：300404 证券简称：博济医药 公告编号：2024-088 博济医药科技股份有限公司 关于计提资产减值损失、信用减值损失及核销资产的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次计提资产减值损失、信用减值损失情况概述 （一）本次计提资产减值损失、信用减值损失的原因 博济医药科技股份有限公司（以下简称"公司"）本次计提资产减值准备， 是依照《企业会计准则》及公司会计政策的相关规定进行的。公司及下属子公司 对 2024 年半年度末各类存货、应收款项、合同资产、固定资产、在建工程、无 形资产、商誉、持有待售资产等资产进行了全面清查，对各类存货的可变现净值、 应收款项及合同资产回收的可能性、固定资产、在建工程、无形资产及持有待售 资产的可变现性进行了充分的评估和分析，认为上述资产中部分资产存在一定的 减值迹象，本着谨慎性原则，公司需对可能发生资产减值损失的相关资产进行计 提减值准备。 公司及下属子公司对 2024 年半年度末存在可能发生减值迹象的资产（范围 包括合同资产、存货）进行全面清查和资产 ...